Temodal is the European brand name for temozolomide (Temodar). Indicated for: Newly diagnosed glioblastoma multiforme (GBM) in adults with initial concomitant chemoradiotherapy followed by 6 cycles of maintenance temozolomide. Recurrent/progressive malignant glioma (anaplastic astrocytoma) after standard therapy.
Concomitant phase: 75 mg/m² daily for 42 days with radiotherapy. Maintenance phase: 150–200 mg/m² daily for 5 days of 28-day cycle for 6 cycles.
Myelosuppression: Monitor CBC. Pneumocystis jiroveci Pneumonia (PCP): Prophylaxis required during concomitant phase. Hepatotoxicity: Monitor LFTs. Embryo-Fetal Toxicity.
Nausea (49%), fatigue (45%), vomiting (29%), headache (25%), constipation (23%), anorexia (19%), thrombocytopenia (19%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
Temozolomide is an imidazotetrazine derivative that undergoes rapid chemical conversion at physiologic pH to the reactive alkylating agent MTIC. MTIC methylates DNA predominantly at the O6 and N7 positions of guanine, causing DNA strand breaks and triggering apoptosis. Methylation silencing of the MGMT gene promoter predicts benefit from temozolomide.
Half-life: ~1.8 hrs. Route: Oral. Refer to the full prescribing information for complete pharmacokinetic data.
Clinical efficacy and safety data are available in the full prescribing information and referenced publications.
Temodal is the European brand name for temozolomide (Temodar). Indicated for: Newly diagnosed glioblastoma multiforme (GBM) in adults with initial concomitant chemoradiotherapy followed by 6 cycles of maintenance temozolomide. Recurrent/progressive malignant glioma (anaplastic astrocytoma) after standard therapy.
Temozolomide is an imidazotetrazine derivative that undergoes rapid chemical conversion at physiologic pH to the reactive alkylating agent MTIC. MTIC methylates DNA predominantly at the O6 and N7 positions of guanine, causing DNA strand breaks and triggering apoptosis. Methylation silencing of the MGMT gene promoter predicts benefit from temozolomide.
Nausea (49%), fatigue (45%), vomiting (29%), headache (25%), constipation (23%), anorexia (19%), thrombocytopenia (19%)